Fingerprint
Dive into the research topics of 'Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
Antoni Ribas*, Richard Kefford, Margaret A. Marshall, Cornelis J.A. Punt, John B. Haanen, Maribel Marmol, Claus Garbe, Helen Gogas, Jacob Schachter, Gerald Linette, Paul Lorigan, Kari L. Kendra, Michele Maio, Uwe Trefzer, Michael Smylie, Grant A. McArthur, Brigitte Dreno, Paul D. Nathan, Jacek MacKiewicz, John M. Kirkwood
*Corresponding author for this work
- University of California at Los Angeles
- University of Sydney
- Pfizer
- Radboud University Nijmegen
- Netherlands Cancer Institute
- Hospital Clinic Barcelona
- University of Tübingen
- National and Kapodistrian University of Athens
- Sheba Medical Center at Tel Hashomer
- Washington University St. Louis
- The Christie NHS Foundation Trust
- Ohio State University
- Azienda Ospedaliera Universitaria Senese
- Charité – Universitätsmedizin Berlin
- University of Alberta
- Peter Maccallum Cancer Centre
- CHU de Nantes
- The Hillingdon Hospitals NHS Foundation Trust
- University of Medical Sciences Poznan
- University of Pittsburgh
- Kiel University
Research output: Contribution to journal › Article › peer-review
682
Scopus
citations